XTL Biopharmaceuticals Advances NeuroNOS Acquisition and Plans $2 Million Private Placement to Address Nasdaq Equity Deficiency

The latest announcement is out from XTL Biopharmaceuticals Sponsored ADR ( (XTLB) ).

On January 28, 2026, XTL Biopharmaceuticals Ltd. announced it is moving ahead with the planned acquisition of 85% of NeuroNOS Ltd. from Beyond Air Inc., following a binding letter of intent signed on January 13, 2026, and has scheduled a shareholders’ meeting for February 17, 2026 to seek approval for a private placement of up to $2 million. Management believes that completing the NeuroNOS acquisition alongside the private placement will help remedy the company’s current deficiency under Nasdaq Listing Rule 5550(b)(1) regarding the minimum stockholders’ equity requirement of $2.5 million, though XTL cautioned there is no assurance the deal will close, the financing will be approved, or that Nasdaq will accept its compliance plan or maintain its listing, underscoring ongoing listing and financing risk for investors and other stakeholders.

Spark’s Take on XTLB Stock

According to Spark, TipRanks’ AI Analyst, XTLB is a Underperform.

XTL Biopharmaceuticals Ltd. shows considerable financial difficulties with persistent losses and weak cash flow. The technical analysis aligns with a bearish outlook, while valuation metrics highlight an unattractive investment at present. Although the stock has seen a recent price surge, the absence of earnings call details makes future performance uncertain.

To see Spark’s full report on XTLB stock, click here.

More about XTL Biopharmaceuticals Sponsored ADR

XTL Biopharmaceuticals Ltd. is an Israel-based biopharmaceutical company whose shares trade on Nasdaq as a foreign private issuer. The company operates in the life sciences sector and focuses on the development and commercialization of pharmaceutical therapies, positioning itself within the broader biotech and drug development industry.

Average Trading Volume: 716,720

Technical Sentiment Signal: Sell

Current Market Cap: $9.14M

For detailed information about XTLB stock, go to TipRanks’ Stock Analysis page.